Innovassynth technologies (India) Limited has announced a change in its corporate website following the completion of its merger and name change process. The company informed BSE Limited on March 20, 2026, about the website transition as part of its regulatory compliance obligations.

Corporate Restructuring Details

The website change stems from the company's recent corporate restructuring activities. The scheme of merger by absorption involved Innovassynth Technologies (India) Limited merging with and into Innovassynth Investments Limited, followed by a name change of the merged entity from "Innovassynth Investments Limited" to "Innovassynth Technologies (India) Limited."

Website Transition Information

The company has provided specific details about the website change to ensure stakeholder awareness:

Regulatory Compliance

The notification was made pursuant to Regulation 30 read with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the new website is fully functional and contains all information required under Regulation 46 of the SEBI LODR.

Company Operations

Innovassynth Technologies (India) Limited operates from two locations. The registered office is located at Old Mumbai-Pune Road, Khopoli, while the corporate office is situated at TCG International Biotech Park, Genesis Square, Hinjewadi Phase – II, Pune. The communication was signed by Sameer Pakhali, Company Secretary & Compliance Officer, who holds ACS certification number 55746.

Innovassynth investments announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing challenging operational performance despite completing a significant corporate restructuring. The company, formerly known as Innovassynth Investments Limited, reported substantial losses during the reporting period.

Financial Performance Overview

The company's financial performance showed mixed results across different metrics during Q3FY26:

Nine-Month Performance Analysis

The nine-month period ending December 31, 2025, demonstrated significant operational challenges:

Merger Completion and Corporate Restructuring

A significant development during the quarter was the completion of the merger by absorption of associate company Innovassynth Technologies (India) Limited. The National Company Law Tribunal approved the scheme on November 14, 2025, with the merger becoming effective on December 19, 2025, when the order was filed with the Registrar of Companies.

As part of this merger, the company issued 4,74,65,031 additional equity shares with a face value of Rs. 10 each at an issue price of Rs. 29.39 each to erstwhile shareholders. This resulted in an increase in share capital by Rs. 13,949.97 lakh, comprising face value of Rs. 4,746.50 lakh and securities premium of Rs. 9,203.47 lakh.

Operational Expenses and Cost Structure

The company's expense structure during Q3FY26 included several key components:

• Cost of materials consumed: Rs. 1,468.42 lakh • Employee benefits expense: Rs. 920.68 lakh • Other expenses: Rs. 1,329.65 lakh • Finance costs: Rs. 188.83 lakh • Depreciation and amortisation: Rs. 197.39 lakh

Notably, the company recorded a positive impact from changes in inventories of Rs. 1,114.49 lakh, which partially offset other operational expenses.

Regulatory and Compliance Matters

The company disclosed the impact of New Labour Codes that became effective November 21, 2025. The consolidated labour legislation framework resulted in an incremental impact of Rs. 92.12 lakh on employee benefit expenses for the quarter and nine months ended December 31, 2025, primarily due to changes in wage definitions and recognition of past service costs.

Exceptional items totaling Rs. 50.22 lakh were recorded during the quarter, primarily related to merger-related expenses. The company's main business involves manufacturing specialty chemicals and pharmaceutical intermediates, with all other activities being incidental to the core operations.